News | January 28, 2014

ReCor Medical Advances Ultrasound-Based Renal Denervation System

ReCor Medical Paradise System Renal Denervation RDN Therapy Hypertension

January 28, 2014 — ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant hypertension (HTN).
 
The company received CE marking for the latest generation of its ultrasound-based renal denervation system. Patients were treated with the system in December 2013 at the Universitats–Herzzentrum, Bad Krozingen, Germany by Prof. Thomas Zeller, M.D. and Elias Noory, M.D.
 
"The initial procedures with the Paradise System highlighted the generator's ability to automatically customize energy delivery based on the patient's artery size while maintaining a consistent level of cooling protection," Zeller and  Noory said.
 
Drs. Nicolas Van Mieghem and Joost Daemen, Erasmus Medical Center in Rotterdam, the Netherlands, used for the first time ReCor's Radiance catheter line, which is 5 French and rapid-exchange compatible to be introduced in the radial artery.
 
"Last Friday's procedures using the new Radiance catheter with access via the radial artery marks a significant new approach to making the RDN procedure quicker, safer and potentially more cost-effective for hospitals and patients," they said. “This system's radial artery access and 10 second ablation time should allow us to treat a patient in a minimally invasive way within 30 minutes, and then let that patient go home the same day."
 
The Paradise System uses radial ultrasound as its energy source with water-based convective cooling.
 
For more information: www.recormedical.com

Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now